← Evidence map

ArticleEClinicalMedicine2026

Cediranib with weekly paclitaxel or olaparib versus weekly paclitaxel for advanced or recurrent endometrial cancer (COPELIA): a multicentre, open-label, randomised, phase 2 trial in the UK.

Robert D Morgan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Cediranib with weekly paclitaxel or olaparib versus weekly paclitaxel for advanced or recurrent endometrial cancer (COPELIA): a multicentre, open-label, randomised, phase 2 trial in the UK. | Socratic